Advertisement Sanofi launches generic version of Eloxatin - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sanofi launches generic version of Eloxatin

Sanofi US, through its generics division Winthrop US, has launched an authorized generic version of Eloxatin (oxaliplatin injection).

The company said that the authorized generic version’s formulation is same as the original drug, Eloxatin, for which it holds the original patent.

Eloxatin is a platinum-based drug, which is used in combination with infusional 5-fluorouracil/leucovorin.

The drug is indicated for the treatment of colorectal cancer or can be used as adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

The authorized generic version of Eloxatin is said to be available in 50mg and 100mg single-use vials.

Sanofi North America chief medical officer Charles Hugh-Jones said the company is committed to broadening access to its medicines and providing more affordable treatment options for patients.

"The availability of an authorized generic version of Eloxatin is welcomed news for patients and physicians alike," Hugh-Jones said.

According to Sanofi, Eloxatin can cause serious allergic reactions, including allergic reactions that may cause death.

It may cause nerve problems and can create a rare condition that affects the brain called Reversible Posterior Leukoencephalopathy (RPLS).

Eloxatin may also cause liver problems (hepatotoxicity) and can cause a decrease in white blood cells, which can lead to infections.